<DOC>
	<DOCNO>NCT00951223</DOCNO>
	<brief_summary>This observational prospective registry design evaluate safety , adherence , efficacy prescribe , patient-administered therapy Infergen® ( Interferon alfacon 1 ) prescribe therapy patient chronically infected HCV . The primary endpoint efficacy SVR rate 24 week therapy end .</brief_summary>
	<brief_title>Observational Prospective Registry Efficacy , Safety , Adherence Infergen® Patients Infected With Hep C</brief_title>
	<detailed_description>This registry plan enroll 1000 patient 75 clinical site across United States . Potentially eligible patient anti-HCV antibody-positive detectable serum plasma HCV RNA . Patients HCV genotype ; also antiviral treatment-naïve history either nonresponse relapse previous antiviral therapy . Patients roll directly current interferon ( IFN ) therapy registry Infergen therapy , average washout period &lt; 1 month . Rollovers occur 4 , 12 , 24 week IFN therapy . Patients coinfected HBV HIV include registry . Each investigator participate registry employ discretion standard clinical practice determine see patient clinic , manage patient 's drug regimen , best monitor patient 's response tolerance therapy.The decision enroll patient start therapy Infergen prescribe therapy may guide historic biopsy result , patient undergo liver biopsy investigator 's discretion . Biopsy prerequisite , however , investigator believe unnecessary . When patient 's treatment expect require significant dose modification and/or intensive monitor comorbid condition , enrol patient registry investigator 's discretion . For purpose registry , data collect baseline ; Weeks 4 , 12 , 24 , 48 start therapy ; follow-up visit 4 24 week treatment end . Safety assess monitor AEs , reduction/discontinuation therapy AEs , routine laboratory result mean determined investigator . Adherence course therapy also evaluate , take account physician-directed dose reduction cessation , patient ' self-reports compliance , return use unused medication schedule visit .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Willing consent data collect provided Duke Clinical Research Institute ( DCRI ) Three Rivers Pharmaceuticals 2 . Able willing give write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization , comply requirement registry protocol 3 . AntiHCV antibodypositive 4 . HCV RNA concentration &gt; 100,000 IU/mL reverse transcriptasepolymerase chain reaction ( RTPCR ) assay baseline &gt; 90 day baseline visit 5 . Deemed investigator appropriate patient treatment Infergen prescribe medication 6 . Baseline CD4 count &gt; 200 cells/mm3 ( human immunodeficiency virus [ HIV ] HCV coinfected patient ) 7 . Women : must document surgically sterile , postmenopausal ( define &gt; 2 year without menses ) , agree use 2 form effective contraception registry 6 month receive final dose study drug . Men : must agree use 2 form effective contraception registry 6 month receive final dose study drug , partner childbearing potential must pregnant screening . 8 . Women : must lactate , childbearing potential , must negative serum pregnancy test result baseline visit 9 . Age &gt; 18 year 1 . Unable complete clinic visit comply registry procedure , include selfinjection Infergen 2 . Known hypersensitivity alphainterferons component product 3 . Decompensated hepatic disease 4 . Autoimmune hepatitis 5 . Hemoglobinopathies ( i.e. , thalassemia sickle cell anemia ) 6 . Any condition , opinion investigator , would make patient unsuitable enrollment could interfere patient participate complete registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>